tetrandrine Report issue

Small molecule Experimental

Active Ingredient History

NOW
  • Now
Tetrandrine, isolated from the root of Stephania tetrandra S Moore, is a traditional Chinese clinical agent for silicosis, autoimmune disorders, inflammatory pulmonary diseases, cardiovascular diseases and hypertension. Tetrandrine is a potent MDR-reversing agent and is an ABCB1/ABCC1 inhibitor. Tetrandrine (CBT-1) is being developed by CBA Pharma, as an adjunctive therapy to chemotherapy in various cancer types with multiple drug resistance (MDR), including acute myelogenous leukemia , Breast, Non-Hodgkin’s Lymphoma, Hodgkin’s disease, Non-Small Cell Lung Cancer, Multiple Myeloma, Gallbladder, Pancreatic, Gastrointestinal Tract, Small Cell Lung Cancer, Bladder, Head & Neck, and Sarcoma.   NCATS

Chemistry

  • SMILES: COC1=CC=C2C[C@@H]3N(C)CCC4=C3C(OC5=CC6=C(CCN(C)[C@H]6CC7=CC=C(OC1=C2)C=C7)C=C5OC)=C(OC)C(OC)=C4
  • InChIKey: WVTKBKWTSCPRNU-KYJUHHDHSA-N
  • Mol. Mass: 622.7499
  • ALogP: Missing data
  • ChEMBL Molecules: Missing data
More Chemistry

Pharmacology

Organizations (2)

Research & Development (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (7)

Approved Indications (1)


 

Neoplasms

Experimental Indications - Clinical Trial Phases 1-4 (6)


 

Carcinoma, Non-Small-Cell Lung (Phase 3)

COVID-19 (Phase 4)

Mycobacterium tuberculosis ()

Nasopharyngeal Carcinoma (Phase 2)

Osteosarcoma (Phase 1)

Silicosis ()

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial Organizations: 2

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue